Drug costs are a problem for a greater share of women than men
Source 2017 Kaiser Women's Health Survey…
View the Latest: Prescription Drugs
Filter
-
-
Analysis: Cost of Treating Opioid Addiction Rose Rapidly for Large Employers as the Number of Prescriptions Has Declined
News ReleaseA new Kaiser Family Foundation analysis finds that while the use of prescription opioids among people with employer-based health coverage has declined to its lowest levels in over a decade, the cost of treating addiction and overdoses has increased sharply.
-
HIV and the Opioid Epidemic: 5 Key Points
Issue BriefThis chart series highlights 5 key things to know about the intersection of the nation’s HIV and opioid epidemics.
-
JAMA Forum: The Partisan Divide on Health Care
PerspectiveIn this post for JAMA, the Kaiser Family Foundation's Larry Levitt outlines the health care platforms of the Republican and Democratic parties, noting their fundamentally different aims and differing ideas about, among other things, the Affordable Care Act (also known as Obamacare) and Medicare.
-
Medicaid’s Most Costly Outpatient Drugs
Issue BriefUsing Medicaid State Drug Utilization Data, this brief presents the 50 most costly drugs before rebates used by the Medicaid program over the January 2014 through June 2015 period. It then examines reasons why these drugs are so costly; explores case studies on opioids, hepatitis C drugs, and the drug Abilify; and considers policy implications.
-
KFF Health Tracking Poll October 2022: The Issues Motivating Voters One Month Before The Midterm Elections
FeatureLeading up to the November 2022 midterm elections, abortion access is motivating majorities of Democratic women, women under 50 and and Democratic voters in states with abortion bans. For older voters, some health care issues related to Medicare costs are resonating.
-
Medicaid and the Inflation Reduction Act of 2022
Policy WatchThe recent passage of the Inflation Reduction Act of 2022 (IRA) includes a number of climate, tax, and health care provisions and prescription drug reforms. This policy watch explores the potential impacts of the Inflation Reduction Act on overall Medicaid spending as well as implications for Medicaid beneficiaries.
-
How Will the Prescription Drug Provisions in the Inflation Reduction Act Affect Medicare Beneficiaries?
Issue BriefThe brief provides a quick explainer of the prescription drug provisions in the Inflation Reduction Act signed into law on August 16, 2022 and presents new estimates on how many Medicare beneficiaries could be helped by those provisions.
-
Key Facts About Medicare Part D Enrollment and Costs in 2022
Issue BriefThis analysis provides the latest data about Medicare Part D enrollment, premiums, and cost sharing in 2022 and trends over time, including information about stand-alone prescription drug plans (PDPs) and Medicare Advantage prescription drug plans.
-
What Are the Prescription Drug Provisions in the Inflation Reduction Act?
FeatureThis slideshow explains the prescription drug provisions proposed in the Inflation Reduction Act as passed by the Senate